Evidence map›Paper›PMID 37431853›Full record

ArticleAllergy2023

Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019.

Youn Ho Shin, Jimin Hwang, Rosie Kwon, Seung Won Lee, Min Seo Kim, GBD 2019 Allergic Disorders Collaborators, Jae Il Shin, Dong Keon Yon

Open access · bronzeAbstract read
In one paragraph

Article in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 8 pooled it
61.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

216 citing papers in PubMed, 8 syntheses or guidelines pooled it, 351 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Probiotics in infants for prevention of allergic disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

156 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Youn Ho ShinDepartment of Pediatrics, The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, South Korea.ORCID 0000-0003-2326-1820
Jimin HwangDepartment of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
Rosie KwonCenter for Digital Health, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Seung Won LeeDepartment of Precision Medicine, Sungkyunkwan University, Suwon, South Korea.ORCID 0000-0001-5632-5208
Min Seo KimDepartment of Digital Health, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, South Korea.
GBD 2019 Allergic Disorders Collaborators
Jae Il ShinDepartment of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.
Dong Keon YonCenter for Digital Health, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.ORCID 0000-0003-1628-9948
Yonsei University · KRBroad Institute · USJohns Hopkins University · USKyung Hee University · KRKyung Hee University Medical Center · KRSungkyunkwan University · KRThe Catholic University of Korea Yeouido St. Mary's Hospital · KR

Funding

THE GLOBAL BURDEN OF DISEASE 2000 IN AGING POPULATIONSP01AG017625 · NIA · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI MURRAY, CHRISTOPHER J.L. · 2000 to 2004
$9.4M
NIA NIH HHS P01 AG017625
6 · The paper itself

Abstract

backgroundAsthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national, and temporal trends of the burden of asthma and AD from 1990 to 2019 and analyze their associations with geographic, demographic, social, and clinical factors.

methodsUsing data from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019, we assessed the age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of both asthma and AD from 1990 to 2019, stratified by geographic region, age, sex, and socio-demographic index (SDI). DALYs were calculated as the sum of years lived with disability and years of life lost to premature mortality. Additionally, the disease burden of asthma attributable to high body mass index, occupational asthmagens, and smoking was described.

resultsIn 2019, there were a total of 262 million [95% uncertainty interval (UI): 224-309 million] cases of asthma and 171 million [95% UI: 165-178 million] total cases of AD globally; age-standardized prevalence rates were 3416 [95% UI: 2899-4066] and 2277 [95% UI: 2192-2369] per 100,000 population for asthma and AD, respectively, a 24.1% [95% UI: -27.2 to -20.8] decrease for asthma and a 4.3% [95% UI: 3.8-4.8] decrease for AD compared to baseline in 1990. Both asthma and AD had similar trends according to age, with age-specific prevalence rates peaking at age 5-9 years and rising again in adulthood. The prevalence and incidence of asthma and AD were both higher for individuals with higher SDI; however, mortality and DALYs rates of individuals with asthma had a reverse trend, with higher mortality and DALYs rates in those in the lower SDI quintiles. Of the three risk factors, high body mass index contributed to the highest DALYs and deaths due to asthma, accounting for a total of 3.65 million [95% UI: 2.14-5.60 million] asthma DALYs and 75,377 [95% UI: 40,615-122,841] asthma deaths.

conclusionsAsthma and AD continue to cause significant morbidity worldwide, having increased in total prevalence and incidence cases worldwide, but having decreased in age-standardized prevalence rates from 1990 to 2019. Although both are more frequent at younger ages and more prevalent in high-SDI countries, each condition has distinct temporal and regional characteristics. Understanding the temporospatial trends in the disease burden of asthma and AD could guide future policies and interventions to better manage these diseases worldwide and achieve equity in prevention, diagnosis, and treatment.

Indexed as

AsthmaGlobal Burden of DiseaseAdultChildChild, PreschoolGlobal HealthHumansIncidenceMorbidityPrevalenceQuality-Adjusted Life YearsRisk Factorsasthmaatopic dermatitisdisability-adjusted life yearseczemaepidemiologyglobal burdenmortality

Identifiers

PMID37431853
PMCPMC10529296
OpenAlexW4383873008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.